Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

Niharika B. Mettu, Fang‐Shu Ou, Tyler Zemla, +13

JAMA Network Open

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee, +22

Nature Medicine

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Michael J. Overman, Milind Javle, R. Eric Davis, +12

Journal for ImmunoTherapy of Cancer

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Niharika B. Mettu, Erin Twohy, Fang‐Shu Ou, +16

Annals of Oncology

CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study

Francesca Rigiroli, Jocelyn Hoye, Reginald Lerebours, +12

Radiology

The Nuclear Receptor-Coactivator Interaction Surface as a Target for Peptide Antagonists of the Peroxisome Proliferator-Activated Receptors

Niharika B. Mettu, Thomas B. Stanley, Mary A. Dwyer, +4

Molecular Endocrinology

Glucose HomeostasisPeptide ScienceChemical BiologyOxidative StressPeroxisome Proliferator-activated Receptors +18

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

Cara M. Kenney, Tricia Kunst, Santhana Webb, +6

Investigational New Drugs

Abstract CT176: Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors

John M. Kirkwood, Nicholas Iannotti, Daniel Cho, +8

Cancer Research

ImmunologyImmune RegulationImmunoeditingImmunologic MechanismImmunotherapeutics +21

A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).

Michael J. Overman, Charles D. Lopez, Al B. Benson, +17

Journal of Clinical Oncology

Cancer ManagementImmunologyPharmacotherapyImmunotherapeuticsMetastatic Pancreatic Cancer +20

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors

Aung Naing, Alain P. Algazi, Gerald S. Falchook, +11

Cancer